Non-Small Cell Lung Cancer Coverage from Every Angle

AACR COVID-19: Study Finds Age-Related Differences for Survival

By: Joshua D. Madera, MS
Posted: Wednesday, July 29, 2020

Older patients with solid tumors, including lung cancer, appeared to have similar rates of clinical worsening as younger patients, despite differences in clinical presentation, according to a presentation during the 2020 American Association for Cancer Research (AACR) Virtual Meeting on COVID-19 and Cancer (Abstract PO-030). However, older patients with SARS-CoV-2 infection had a worse overall survival as compared with younger patients, according to Laurence Albiges, MD, PhD, of the Gustave Roussy Institute, Villejuif, France, and colleagues.

A total of 137 patients with cancer and suspected of a positive SARS-CoV-2 diagnosis were enrolled in the study. All patients underwent COVID-19 testing. Patients with positive COVID-19 tests were assessed based on their clinical management and overall outcomes.

The investigators reported that the most common cancers identified were solid tumors (92%). These tumors encompassed multiple organ systems, including gastrointestinal (19%), lung (17%), gynecologic (14%), and head/neck (14%). In addition, identification of SARS-CoV-2 infection by reverse transcriptase polymerase chain reaction (97%) and thoracic CT (3%) revealed an increased number of cases in older patients (92%) as compared with younger patients (8%).

Furthermore, the timing and presentation of COVID-19 related symptoms varied between older and younger patients. These symptoms included cough and sputum production (14% in older patients vs. 5% in younger patients), dyspnea (39% vs. 31%), diarrhea (17% vs. 9%), shivers (8% vs. 0%), and sore throat (8% vs. 4%). Moreover, 29% of older patients demonstrated clinical deterioration. Clinical worsening was not impacted by the patients’ age, as older and younger patients had similar disease progression (hazard ratio = 1.157). However, patient age did lead to worse overall survival for older patients (hazard ratio = 2.45).

Disclosure: No information regarding conflicts of interest was provided.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.